Camille Chakiba

Bordeaux, 33000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Journal: Breast (Edinburgh, Scotland)

Published: February 17, 2026

Adenoid Cystic Carcinoma of the Breast and Adjuvant Radiation Therapy: A Review of Literature.

Adenoid Cystic Carcinoma of the Breast and Adjuvant Radiation Therapy: A Review of Literature.

Journal: American journal of clinical oncology

Published: April 23, 2025

Cognitive remediation in breast cancer survivors: A study protocol.

Cognitive remediation in breast cancer survivors: A study protocol.

Journal: Contemporary clinical trials

Published: June 24, 2024

Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer.

Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 20, 2024

Evaluating video-based consultations in routine clinical practice at a comprehensive cancer center.

Evaluating video-based consultations in routine clinical practice at a comprehensive cancer center.

Journal: Acta oncologica (Stockholm, Sweden)

Published: November 10, 2023

Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.

Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.

Journal: Genes, chromosomes & cancer

Published: June 05, 2023

Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.

Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.

Journal: Anticancer research

Published: September 05, 2022

ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.

ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.

Journal: Future oncology (London, England)

Published: June 13, 2022

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Oncology

Published: June 07, 2022

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: May 13, 2022

Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.

Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.

Journal: ESMO open

Published: March 11, 2022

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 20, 2021

Showing 1-12 of 37

Last Updated: 09/26/2026